Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension

Abstract

This review provides moderate-quality evidence that coenzyme Q10 does not have a clinically significant effect on blood pressure. In one of three trials reporting adverse effects, coenzyme Q10 was well tolerated. Due to the small number of individuals and studies available for analysis, more well-conducted trials are needed.

Effects of coenzyme Q10 supplementation on metabolic profile in diabetes: a systematic review and meta-analysis

“…37 In patients with primary hypertension, CoQ 10 significantly lowered systolic and diastolic blood pressures. 37 In patients with primary hypertension, CoQ 10 significantly lowered systolic and diastolic blood pressures.…”

Effect of Monacolin K and COQ10 supplementation in hypertensive and hypercholesterolemic subjects with metabolic syndrome

“…In the meta-analysis by Ho et al, oral treatment with 100 mg/day of coenzyme Q10 decreased SBP by 11 mmHg and DBP by 7 mmHg in subjects with HT [36]. However, the dose of coenzyme Q10 tested is 30 mg and higher than other NCs [37], and in part this explains its possible BP-lowering effect.…”

Nutraceuticals for Serum Lipid and Blood Pressure Control in Hypertensive and Hypercholesterolemic Subjects at Low Cardiovascular Risk

“…Finally, some randomized placebo-controlled clinical trials support the antihypertensive effect of another component of NCs: coenzyme Q10 [21]. In the meta-analysis by Ho et al [22], oral treatment with C100 mg/day of coenzyme Q10 decreased systolic BP by 11 mmHg and diastolic BP by 7 mmHg in subjects with HT. However in our experience, the dose of coenzyme Q10 tested is low (10 mg) and only in part explains its possible BP-lowering effect.…”

“…However in our experience, the dose of coenzyme Q10 tested is low (10 mg) and only in part explains its possible BP-lowering effect. Furthermore, the high costs of coenzyme Q10 and the high doses needed to achieve a significant BP reduction limit its current use as a drug in clinical practice [22]. Finally, it is well known that participation in a clinical study enhances adherence, persistence and effectiveness of antihypertensive agents, particularly in patients with HT taking active treatment rather than those in the control group [3].…”